Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Expansion 2024-2033: Growth Drivers and Dynamics

The poly adp-ribose polymerase (parp) inhibitor global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size –
The poly ADP-ribose polymerase (PARP) inhibitor market size has grown rapidly in recent years. It will grow from 7.52 billion in 2023 to $8.39 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%.  The growth in the historic period can be attributed to clinical research, regulatory approvals, market competition, drug combinations, and patient advocacy.

The poly ADP-ribose polymerase (PARP) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $13.13 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%.  The growth in the forecast period can be attributed to expanded indications, personalized medicine, biomarker development, health economics, and emerging markets. Major trends in the forecast period include precision medicine, immunotherapy advancements, targeted therapies, artificial intelligence in drug discovery, and patient-centric healthcare.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/poly-adp-ribose-polymerase-parp-inhibitor-global-market-report

Scope Of Poly ADP-Ribose Polymerase (PARP) Inhibitor Market
The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

Market Drivers –
The increasing prevalence of ovarian cancer is expected to propel the growth of the poly ADP-ribose polymerase (PARP) inhibitor market going forward. Ovarian cancer refers to a malignant tumor that develops in one or both of a woman’s ovaries, which are part of the female reproductive system responsible for producing eggs and female hormones. Ovarian cancer is growing due to impact of genetic predisposition, an aging population, environmental exposures, and hormonal imbalances. Poly ADP-Ribose Polymerase (PARP) Inhibitors are used in ovarian cancer treatment to target DNA repair mechanisms, specifically in patients with BRCA mutations, leading to synthetic lethality and enhanced tumor cell death. For instance, in February 2022, according to the World Ovarian Cancer Coalition, a Canada-based non-profit organization, ovarian cancer impacted 3.13 million women globally in 2020, and it’s projected to rise by 42% to reach 4.4 million by 2040. Further, over the same period, there’s expected to be a 51% surge in ovarian cancer-related deaths, climbing from 2.07 in 2020 to 3.13 in 2040. Therefore, the increasing prevalence of ovarian cancer is driving the growth of the poly ADP-ribose polymerase (PARP) inhibitor market.

Market Trends –
Major companies operating in the poly ADP-ribose polymerase (PARP) inhibitor market are developing generic PARP inhibitors to offer a tailored treatment approach for cancer patients with specific genetic mutations. Generic PARP inhibitors are medications that block the activity of the enzyme poly ADP-ribose polymerase (PARP). For instance, in March 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Olaparib, a PARP inhibitor under the IBYRA brand, aiming to enhance accessibility to advanced cancer treatment. IBYRA targets specific genetic mutations found in breast, ovarian, prostate, and pancreatic cancers, offering a tailored and effective treatment approach. The drug is particularly beneficial for patients with HRD-positive or BRACA mutations, helping to delay disease progression.

The poly ADP-ribose polymerase (PARP) inhibitor market covered in this report is segmented –

1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Get an inside scoop of the poly adp-ribose polymerase (parp) inhibitor market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample_request?id=15637&type=smp

Regional Insights –
North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies –
Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are  Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc

Table of Contents
1. Executive Summary
2. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report Structure
3. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Trends And Strategies
4. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market – Macro Economic Scenario
5. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Size And Growth
…..
27. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model